Safety, Tolerability, and Effects of a Single Subcutaneous Administration of SP16 – a SERPIN-like, Small Peptide Agonist of the Low-Density Lipoprotein–like Receptor 1– on the Acute Inflammatory Response in Patients With ST-Segment Elevation Myocardial Infarction

A single subcutaneous administration of SP16, a synthetic targeted LRP1 agonist, was safe and well-tolerated in patients with STEMI. A trend toward reduction in the inflammatory response and infarct size with SP16 was noted; however, the sample size for this study was not based on formal statistical criteria. More extensive studies are planned to determine the clinical efficacy of SP16 in STEMI.NCT: NCT04225533.